Tivozanib: ¿hace falta un nuevo Tki en 1L de RCC?

7 / 38

Not all are good news…
• Phase III trial of sunitinib1:
– 19% of discontinuations.
– 50% dose reductions.
• Phase III Comparz Trial2 :
– 24% of discontinuations with Pazopanib, 20% with sunitinib
– 44% dose reductions with Pazopanib, 51% with sunitinib
• Phase II Cabosun Trial3:
– 21% of discontinuations with Cabozantinib and 22% with sunitinib
– 46% dose reductions with Cabozantinib and 35% with sunitinib
• Phase III trial CheckMate 2244:
– 22% of discontinuations with Nivo/Ipi and 15% with sunitinib.
– 53% dose reductions of sunitinib
Motzer R, et al. NEJM 2006 ; Motzer R, et al. NEJM 2013; Choueiri T, et al. J Clin Oncol 2017; Motzer R ,et al. NEJM 2018
50% dose
reductions &
20%
discontinuations